摘要
目的观察西药联合丹龙口服液治疗轻、中度支气管哮喘急性发作期(热哮证)的有效性和安全性。方法选择轻、中度支气管哮喘急性发作期(热哮证)患者480例,按3∶1随机分为试验组(360例)和对照组(120例),两组均维持原西药治疗,试验组予丹龙口服液,对照组予咳喘宁口服液,均口服,10 m L/次,3次/日,治疗7天,评价哮喘症状疗效、肺功能疗效、中医证候计分和及主症计分。结果哮喘症状疗效比较,控显率试验组(77.36%,246/318)高于对照组(56.07%,60/107);肺功能疗效比较,控显率试验组(74.28%,231/318)高于对照组(50.00%,51/107);中医证候计分治疗前后差值比较,试验组[(-11.26±4.70)分]优于对照组[(-9.21±5.09)分];中医主症计分治疗前后差值比较,试验组[(-6.58±3.08)分]优于对照组[(-5.16±3.45)分],差异均有统计学意义(P<0.01)。不良反应发生率,试验组为6/346例(1.73%),对照组为12/118例(10.17%),差异有统计学意义(P<0.05)。结论西药联合丹龙口服液治疗轻、中度支气管哮喘急性发作期(热哮证)优于咳喘宁口服液。
Objective To observe the efficacy and safety of Danlong Oral Liquid （DOL） com- bined Western medicine （WM） in treating mild-to-moderate bronchial asthma patients （heat wheezing syndrome） at acute onset. Methods Totally 480 mild-to-moderate bronchial asthma patients （heat wheezing syndrome） at acute onset were randomly assigned to two groups in the ratio 3： 1, the treatment group （360 cases） and the control group （120 cases）. All patients received basic WM treatment. Patients in the treatment group took DOL, 10 mL each time, 3 times per day for 7 days in total, while those in the control group took Kechuanning Oral Liquid （KOL）, 10 mL each time, 3 times per day for 7 days in total. Efficacy for asthma symptoms, lung functions and scores of TCM syndrome and/or main symptoms were evaluated. Results The percentage of clinical control and significant effectiveness of asthma symptoms in the treatment group was significantly higher than that of the control group （77.36% vs 56.07%, P 〈0.01 ）. The percentage of clinical control and significant effectiveness of lung functions in the treat- ment group was significantly higher than that of the control group （74.28% vs 50.00%, P 〈0.01 ）. The anterior-posterior difference in scores of TCM syndrome was significantly superior in the treatment group than in the control group （ -11.26±4.70 vs -9.21±5.09, P 〈0.01 ）. The anterior-posterior difference in scores of main symptoms was significantly better in the treatment group than in the control group （ -6.58±3.08 vs -5.16±3.45, P 〈0.01 ）. The incidence of adverse reactions was significantly lower in the treatment group than in the control group [1. 73% （6/346 cases） vs 10.17% （12/118 cases）, P 〈 0.05]. Conclusion DOL combined WM was superior to KOL in treating mild-to-moderate bronchial asthma patients （heat wheezing syndrome） at acute onset.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2015年第5期529-533,共5页
Chinese Journal of Integrated Traditional and Western Medicine
关键词
支气管哮喘
急性发作
热哮证
丹龙口服液
bronchial asthma
acute attack
heat wheezing syndrome
Danlong Oral Liquid
